Method for inhibiting the maturation of dendritic cells
OwnerUlrich Schubert, Elisabeth Zinser +1inventors
InventorsUlrich Schubert, Elisabeth Zinser, Alexander Steinkasserer
Life of this patent
Estimating the term…
Abstract
Proteasome inhibitors (PI) are used for inhibiting the maturation of dendritic cells (DZ) and thus in the treatment or the prophylaxis of allergies, asthma, tissue or transplant rejection or autoimmune diseases. The concentration of the proteasome inhibitors lies preferably in the range of 10 nM to 10 μM, based on the peripheral blood or the cytoplasm.
Claims24
-8. (canceled)
A proteasome inhibitor which is capable of producing an agent for treatment or prevention of at least one disease selected from the group consisting of
- a) an allergy,
- b) asthma,
- c) a tissue rejection or transplant rejection, and
- d) an autoimmune disease.
A method of treating or preventing a malfunction of a cellular immune system, comprising:
- providing a proteasome inhibitor to treat or prevent said malfunction of said cellular immune system,
- wherein dendritic cells and/or T cells and/or Th17 cells and/or B cells are involved in said malfunction of said cellular immune system.
A method of treating or preventing a disease, comprising:
- providing a proteasome inhibitor capable of producing an agent for treatment or prevention of at least one disease selected from the group consisting of
- a) an allergy,
- b) asthma,
- c) a tissue rejection or transplant rejection, and
- d) an autoimmune disease.
Dependencies are inferred from the claim text.